PTPRJ and non-small cell lung carcinoma: To understand if our findings might have a clinical significance, we interrogated the clinical public database canEvolve (www.canevolve.org): non-small cell lung cancer patients who experienced the longest survival rate showed lower SLC3A2 and higher PTPRJ gene expression compared to patients with dismal prognosis that, in turn, exhibited the highest and the lowest SLC3A2 and PTPRJ gene expression, respectively (Figure 6A and 6B).